These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 1733346)

  • 1. A novel biotinylated probe specific for hyaluronate. Its diagnostic value in diffuse malignant mesothelioma.
    Azumi N; Underhill CB; Kagan E; Sheibani K
    Am J Surg Pathol; 1992 Feb; 16(2):116-21. PubMed ID: 1733346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyaluronate binding probe and CD44 in the differential diagnosis of malignant effusions: disappointing results in cytology material.
    Filie AC; Abati A; Fetsch P; Azumi N
    Diagn Cytopathol; 1998 Jun; 18(6):473-4. PubMed ID: 9626526
    [No Abstract]   [Full Text] [Related]  

  • 3. Mesotheliomas show higher hyaluronan positivity around tumor cells than metastatic pulmonary adenocarcinomas.
    Törrönen K; Soini Y; Pääkkö P; Parkkinen J; Sironen R; Rilla K
    Histol Histopathol; 2016 Oct; 31(10):1113-22. PubMed ID: 26912058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoreactivity for BER-EP4 in adenocarcinomas, adenomatoid tumors, and malignant mesotheliomas.
    Gaffey MJ; Mills SE; Swanson PE; Zarbo RJ; Shah AR; Wick MR
    Am J Surg Pathol; 1992 Jun; 16(6):593-9. PubMed ID: 1599037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies.
    Abutaily AS; Addis BJ; Roche WR
    J Clin Pathol; 2002 Sep; 55(9):662-8. PubMed ID: 12194995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical phenotype of malignant mesothelioma: predictive value of CA125 and HBME-1 expression.
    Bateman AC; al-Talib RK; Newman T; Williams JH; Herbert A
    Histopathology; 1997 Jan; 30(1):49-56. PubMed ID: 9023557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calretinin: a novel immunocytochemical marker for mesothelioma.
    Doglioni C; Dei Tos AP; Laurino L; Iuzzolino P; Chiarelli C; Celio MR; Viale G
    Am J Surg Pathol; 1996 Sep; 20(9):1037-46. PubMed ID: 8764740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of membranous staining of mesothelioma.
    King JA; Tucker JA
    Cell Vis; 1998; 5(1):24-7. PubMed ID: 9660721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of cytokeratins 20 and 7 in discriminating metastatic adenocarcinomas from pleural mesotheliomas.
    Tot T
    Cancer; 2001 Nov; 92(10):2727-32. PubMed ID: 11745209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Claudin-4 immunohistochemistry is highly effective in distinguishing adenocarcinoma from malignant mesothelioma in effusion cytology.
    Jo VY; Cibas ES; Pinkus GS
    Cancer Cytopathol; 2014 Apr; 122(4):299-306. PubMed ID: 24421209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood group antigens, Lewisx and Lewisy in the diagnostic discrimination of malignant mesothelioma versus adenocarcinoma.
    Jordon D; Jagirdar J; Kaneko M
    Am J Pathol; 1989 Nov; 135(5):931-7. PubMed ID: 2817084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinctive microvillous brush border staining with HBME-1 distinguishes pleural mesotheliomas from pulmonary adenocarcinomas.
    Dahlstrom JE; Maxwell LE; Brodie N; Zardawi IM; Jain S
    Pathology; 2001 Aug; 33(3):287-91. PubMed ID: 11523926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinguishing malignant mesothelioma from pulmonary adenocarcinoma: an immuno-histochemical approach using a panel of monoclonal antibodies.
    Tuttle SE; Lucas JG; Bucci DM; Schlom J; Primus J
    J Surg Oncol; 1990 Oct; 45(2):72-8. PubMed ID: 2214794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "Thick" cell membranes revealed by immunocytochemical staining: a clue to the diagnosis of mesothelioma.
    Leong AS; Parkinson R; Milios J
    Diagn Cytopathol; 1990; 6(1):9-13. PubMed ID: 2323301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GATA3 Immunohistochemistry for Distinguishing Sarcomatoid and Desmoplastic Mesothelioma From Sarcomatoid Carcinoma of the Lung.
    Berg KB; Churg A
    Am J Surg Pathol; 2017 Sep; 41(9):1221-1225. PubMed ID: 28614203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Claudins in differential diagnosis between mesothelioma and metastatic adenocarcinoma of the pleura.
    Soini Y; Kinnula V; Kahlos K; Pääkkö P
    J Clin Pathol; 2006 Mar; 59(3):250-4. PubMed ID: 16505274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma.
    Brown RW; Clark GM; Tandon AK; Allred DC
    Hum Pathol; 1993 Apr; 24(4):347-54. PubMed ID: 7684019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ber-EP4 antibody as a discriminant in the differential diagnosis of malignant mesothelioma versus adenocarcinoma.
    Sheibani K; Shin SS; Kezirian J; Weiss LM
    Am J Surg Pathol; 1991 Aug; 15(8):779-84. PubMed ID: 2069213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical analysis of nuclear versus cytoplasmic staining of WT1 in malignant mesotheliomas and primary pulmonary adenocarcinomas.
    Foster MR; Johnson JE; Olson SJ; Allred DC
    Arch Pathol Lab Med; 2001 Oct; 125(10):1316-20. PubMed ID: 11570906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melan A (A103) is not a marker of mesothelioma.
    Ordóñez NG; Shen SS; Zenali M; Deavers MT
    Appl Immunohistochem Mol Morphol; 2013 Mar; 21(2):181-4. PubMed ID: 22820661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.